ciltacabtagene autoleucel
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Pronunciation:
sil-ta-kab-ta-jeen aw-toe-loo-sel
Trade Name(s)
- Carvykti
Ther. Class.
Pharm. Class.
CAR-T cell immunotherapies
Indications
Relapsed or refractory multiple myeloma in patients who have received ≥1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Action
A B-cell maturation antigen (BCMA)-directed genetically modified autologous T-cell immunotherapy that involves genetically modifying a patient's own T cells to equip them with chimeric antigen receptors (CARs) to identify and eliminate BCMA-expressing malignant and normal cells.
Therapeutic Effect(s):
Improved progression-free survival.
Pharmacokinetics
Absorption: IV administration results in complete bioavailability.
Distribution: High distribution in the bone marrow.
Metabolism and Excretion: Unknown.
Half-life: 11–15 days
TIME/ACTION PROFILE (concentrations of anti-BCMA CAR T cells)
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| IV | unknown | 12 days | unknown |
Contraindication/Precautions
Contraindicated in:
- Black Box: Active infection;
- Black Box: Inflammatory disorders;
- OB: Pregnancy.
Use Cautiously in:
- Rep: Women of reproductive potential;
- Lactation: Safety not established in breastfeeding;
- Pedi: Safety and effectiveness not established in children.
Adverse Reactions/Side Effects
CV: edema, hypertension, hypotension, tachycardia, arrhythmias
Derm: rash
EENT: nasal congestion, diplopia
F and E: hypophosphatemia, hypocalcemia, hypokalemia, hyponatremia
GI: ↓ appetite, ↑ liver enzymes, constipation, diarrhea, nausea, vomiting, abdominal pain, dysphagia, hyperbilirubinemia, hypoalbuminemia, IMMUNE EFFECTOR CELL–ASSOCIATED ENTEROCOLITIS, vomiting
GU: renal failure
Hemat: bleeding, hypogammaglobulinemia, leukopenia, lymphopenia, neutropenia, thrombocytopenia, anemia, HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS/MACROPHAGE ACTIVATION SYNDROME, lymphocytosis, thrombosis
Metabolic: hypertriglyceridemia
MS: pain, immune-mediated myelitis
Neuro: dizziness, encephalopathy, fatigue, headache, IMMUNE EFFECTOR CELL–ASSOCIATED NEUROTOXICITY SYNDROME (ICANS), insomnia, motor dysfunction, aphasia, ataxia, cranial nerve palsy, delirium, depression, dysgraphia, GUILLAIN-BARRÉ SYNDROME (GBS), headache, micrographia, parkinsonism, peripheral neuropathy, tremor
Resp: cough, dyspnea, hypoxia, upper respiratory tract infection
Misc: chills, CYTOKINE RELEASE SYNDROME (CRS), DEATH, fever, HYPERSENSITIVITY REACTIONS (including anaphylaxis), INFECTION (including hepatitis B reactivation), SECONDARY MALIGNANCY
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Interactions
Drug-Drug
May ↓ antibody response to and ↑ risk of adverse reactions from live vaccines ; use of live vaccines is not recommended for ≥6 wk prior to the start of lymphodepleting chemotherapy, during ciltacabtagene autoleucel treatment, and until immune recovery following treatment with ciltacabtagene autoleucel.
Route/Dosage
IV (Adults): 0.5–1 × 106 CAR-positive viable T cells per kg (max = 1 × 108 CAR-positive viable T cells per single infusion).
Availability
Suspension for injection: 30 mL of frozen suspension of genetically modified autologous T cells in 7.5% dimethyl sulfoxide, 70 mL of frozen suspension of genetically modified autologous T cells in 7.5% dimethyl sulfoxide
Assessment
- Black Box: Monitor for signs/symptoms of CRS at least daily for 2 wk after infusion. If Grade 1 CRS (temperature ≥38° C <72 hr after infusion) occurs, consider treating with tocilizumab 8 mg/kg IV over 1 hr (max = 800 mg). If Grade 2 CRS (temperature ≥38°C with hypotension not requiring vasopressors and/or hypoxia requiring O2 via cannula or blow-by, or Grade 2 organ toxicity) occurs, monitor with continuous telemetry and pulse oximetry; treat as Grade 1, repeating tocilizumab every 8 hr as needed if not responsive to IV fluids up to 1 liter or ↑ supplemental O2 ; consider dexamethasone 10 mg IV every 12–24 hr. If no improvement in 24 hr or rapid progression, repeat tocilizumab and ↑ dose and frequency of dexamethasone (20 mg IV every 6–12 hr). If no improvement in 24 hr or continued rapid progression, switch to methylprednisolone 2 mg/kg IV every 12 hr. After two doses of tocilizumab, consider alternative anticytokine agents. Do not exceed 3 doses of tocilizumab in 24 hr or 4 doses in total. If Grade 3 CRS (temperature ≥38°C with hypotension requiring one vasopressor and/or hypoxia requiring O2 via high-flow nasal cannula, face mask, nonrebreather or venturi; Grade 3 organ toxicity; or Grade 4 transaminitis) occurs, treat as Grades 1 and 2, but consider starting dexamethasone at 10 mg IV every 12 hr. If Grade 4 CRS (temperature ≥38°C with hypotension requiring multiple vasopressors [excluding vasopressin], and/or hypoxia requiring positive pressure, or Grade 4 organ toxicity [excluding transaminitis]) occurs, treat as Grades 1–3, but consider starting dexamethasone at 10 mg IV every 6 hr; if no improvement in 24 hr, consider methylprednisolone 1–2 g IV every 24 hr as needed.
- Black Box: Monitor for neurologic toxicity. If parkinsonism occurs, manage with supportive care. If peripheral neuropathies occur, evaluate for GBS; treat GBS with supportive care, immunoglobulins, and plasma exchange, depending on severity. If myelitis occurs, consider treating with corticosteroid and IV immune globulin. If cranial nerve palsies occur, consider treating with corticosteroid depending on severity and progression.
- Black Box: Monitor for signs and symptoms of ICANS at least daily for 2 wk after infusion. If Grade 1 (ICE score 7–9 or ↓ level of consciousness: awakes spontaneously) occurs, consider dexamethasone 10 mg IV every 12–24 hr for 2–3 days and nonsedating agents for seizure prophylaxis. If Grade 2 (ICE score 3–6 or ↓ level of consciousness: awakes to voice) occurs, administer dexamethasone 10 mg IV every 12 hr for 2–3 days or longer if persistent. If no improvement after 24 hr or toxicity worsens, ↑ dose and/or frequency of dexamethasone (maximum of 20 mg IV every 6 hr). Consider nonsedating agents for seizure prophylaxis. If Grade 3 (ICE score 0–2 or ↓ level of consciousness: awakes only to tactile stimulus; or non-life-threatening seizures; or ↑ intracranial pressure (ICP): focal/local edema on neuroimaging) occurs, administer dexamethasone 10 to 20 mg IV every 6 hr. If no improvement after 24 hr or toxicity worsens, ↑ dexamethasone dose to ≥20 mg IV every 6 hr, OR escalate to high-dose methylprednisolone (1–2 g/day every 24 hr). Consider nonsedating agents for seizure prophylaxis. If cerebral edema is suspected, consider hyperventilation and hyperosmolar therapy. If Grade 4 (ICE score 0: unarousable, stupor, coma, or requires vigorous tactile stimulus; or life-threatening seizures; deep focal motor weakness; ↑ ICP with diffuse cerebral edema, decerebrate/decorticate posturing, cranial nerve VI palsy, papilledema, or Cushing triad) occurs, administer dexamethasone 20 mg IV every 6 hr. If no improvement after 24 hr or toxicity worsens, escalate to high-dose methylprednisolone (1–2 g/day every 24 hr). Consider nonsedating agents for seizure prophylaxis. If cerebral edema is suspected, consider hyperventilation and hyperosmolar therapy, and consider neurology/neurosurgery consult.
- Black Box: Monitor for signs and symptoms of hemophagocytic lymphohistiocytosis/macrophage activation syndrome (hyperferritinemia, hypotension, hypoxia with diffuse alveolar damage, coagulopathy and hemorrhage, cytopenia, multiorgan dysfunction). If symptoms occur, monitor hematologic parameters and treat and transfuse per institutional guidelines.
- Assess for signs/symptoms of infection before and after infusion. Administer prophylactic or therapeutic antimicrobials according to institutional guidelines. If active infection or inflammatory disorder present, do not administer ciltacabtagene autoleucel. If febrile neutropenia occurs, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as indicated.
- Monitor for hypersensitivity reaction (flushing, chest pain, tachycardia, wheezing, tremor, burning sensation, pyrexia, anaphylaxis) for 2 hr after infusion. If reaction occurs, treat promptly as indicated.
- Black Box: Assess for signs and symptoms of immune effector cell–associated enterocolitis (severe or prolonged diarrhea, abdominal pain, weight loss requiring parenteral nutrition). If symptoms occur, consider additional workup to exclude alternative etiologies, and consult gastroenterology and infectious disease specialists.
Lab Test Considerations:
- Verify pregnancy status prior to therapy initiation.
- Black Box: May cause prolonged and recurrent cytopenias. Monitor blood counts prior to and after infusion. If cytopenias occur, treat with growth factors and blood product transfusion according to institutional guidelines.
- Screen for cytomegalovirus, hepatitis B and C viruses, John Cunningham virus, HIV, or any other infectious agents, if clinically indicated, in accordance with guidelines.
- Monitor immunoglobulin levels after therapy. If IgG <400 mg/dL, administer IV immune globulin and antibiotic or antiviral prophylaxis; institute infection precautions.
- Assess disseminated intravascular coagulation; hematology parameters; and pulmonary, cardiac, renal, and hepatic function as clinically indicated and if concerned for CRS.
Implementation
- Live-virus vaccines are not recommended for ≥6 wk prior to the start of lymphodepleting chemotherapy, during therapy, and until immune recovery following ciltacabtagene autoleucel therapy.
- Premedication: Administer oral or IV acetaminophen 650–1000 mg and diphenhydramine 25–50 mg (or equivalent) to all patients 30–60 min prior to infusion. Avoid prophylactic use of systemic corticosteroids.
- Prior to thawing ciltacabtagene autoleucel, confirm that ≥2 doses of tocilizumab and emergency equipment are readily available during and after infusion.
- Confirm patient identity matches the patient identifiers on the ciltacabtagene autoleucel cassette and infusion bag.
IV Administration
- Intermittent Infusion: Place the infusion bag inside a sealable plastic bag (preferably sterile) prior to thawing at 37°C (±2°C) using either a water bath or dry thaw method until there is no visible ice in the infusion bag. Total time from start of thaw until completion should not exceed 15 min. Remove the infusion bag from the plastic bag and wipe dry. Gently mix to disperse clumps of cellular material. Do not prefilter into a different container, wash, spin down, or resuspend in new media prior to infusion. Do not refreeze or refrigerate thawed product. Prime infusion set tubing with 0.9% NaCl; administer the entire contents via central venous access through an in-line filter. Gently mix the contents of the bag during infusion to disperse cell clumps. After infusion, flush with 0.9% NaCl with a volume equal or greater to the total hold-up volume of the primary administration set used, inclusive of the drip tube, to ensure that all product is delivered.
- Rate: Infuse within 2.5 hr.
Patient/Family Teaching
- Explain purpose and side effects of medication to patient. Advise patient to read Patient Information before starting therapy.
- Advise patient to notify health care provider of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care provider before taking other medications.
- Instruct patient to remain within proximity of a health care facility and to avoid driving for ≥2 wk following infusion.
- Counsel patient on the importance of infection prevention measures and to notify health care provider if signs of infection, inflammation or bleeding occur.
- Black Box: Inform patient of the need for lifelong monitoring for secondary malignancies. If secondary malignancy occurs, contact Janssen Biotech, Inc. at 1-800-526-7736 for reporting and to obtain instructions on collection of patient samples.
- Black Box: Advise patient to notify health care provider if signs/symptoms of CRS (chills, fever, confusion, dizziness, diarrhea, headache, difficulty swallowing, joint and muscle pain, nausea, vomiting) occur.
- Black Box: Advise patient to notify health care provider if signs/symptoms of neurologic toxicities (rigid gait, numbness and tingling, weakness, speech changes, seizure) occur.
- Rep: Advise patient to notify health care provider if pregnancy is planned or suspected or if breastfeeding. Advise women of reproductive potential and men with female partners of reproductive potential to use effective method of contraception (IUD or combination of hormonal and barrier methods) from start of mobilization through ≥1 yr after ciltacabtagene autoleucel therapy. Inform patient of risk of infertility with lymphodepleting chemotherapy and of option to cryopreserve semen or ova before therapy.
Evaluation/Desired Outcomes
Improved progression-free survival in patients with elapsed or refractory multiple myeloma.
ciltacabtagene autoleucelis the Nursing Central Word of the day!

Davis's Drug Guide

